Abstract
Identification of a potential genetic susceptibility to cancer and confirmation of a pathogenic gene mutation raises a number of challenging issues for the patient with cancer, their relatives and the health professionals caring for them. The specific risks and management issues associated with rare cancer types have been addressed in the earlier chapters. This chapter considers the wider issues involved in genetic counselling and genetic testing for a genetic susceptibility to cancer for patients, families and health professionals. The first part of the chapter will present the issues raised by the current practice in genetic counselling and genetic testing for cancer susceptibility. The second part of the chapter will address some of the issues raised by the advances in genetic testing technology and the future opportunities provided by personalised medicine and targeted cancer therapy. Facilitating these developments requires closer integration of genomics into mainstream cancer care, challenging the existing paradigm of genetic medicine, adding additional layers of complexity to the risk assessment and management of cancer and presenting wider issues for patients, families, health professionals and clinical services.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
http://www.geneticseducation.nhs.uk/for-practitioners-62/national-occupational-standards (last accessed 20.10.15).
- 2.
https://www.genomicseducation.hee.nhs.uk (last accessed 20.10.15).
- 3.
https://www.abi.org.uk/News/News-releases/2011/04/Insurance-Genetics-Moratorium-extended-to-2017 (last accessed 16.11.15).
- 4.
https://www.23andme.com/en-int/ (last accessed 01.05.15).
- 5.
http://www.agnc.org.uk/information-education/documents,-websites-downloads/ (last accessed 16.11.15).
- 6.
http://www.genomicsengland.co.uk/ (last accessed 21.09.15).
- 7.
http://www.melbournegenomics.org.au/our-work/demonstration-project (last accessed 17.11.15).
References
Alexandrov BL, Nik-Zainai S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421
Alsop K, Fereday S, Meldrum C et al (2014) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. J Clin Oncol 21:2654–2663
ASHG (1975) Genetic counseling. Am J Hum Genet 27:240–242
Ayuso C, Millan J, Mancheno M, Dal-Re R (2013) Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process. Eur J Hum Genet 21(10):1054–1059
Botkin JR, Belmont JW, Berg JS et al (2015) Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 97(1):6–21
British Society for Human Genetics (2010) Report on the genetic testing of children 2010. British Society for Human Genetics
Burton A (2015) Are we ready for direct-to-consumer genetic testing? Lancet Neurol 14:138–139
Chivers Seymour K, Addlington-Hall J, Lucassen AM, Foster CL (2010) What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 19(4):330–342
Chrisitenhusz GM, Devriendt K, Peeters H et al (2014) The communication of secondary variants: interviews with parents whose children have undergone array-CHG testing Clin Genet 86(3):207–216
Clarke A (2010) What is at stake in the predictive genetic testing of children? (2010). Fam Cancer 9(1):19–22
Daniels MS, Urbauer DL, Stanley JL et al (2009) Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer. Genet Med 11(9):624–628
Forrest K, Simpson SA, Wilson BJ et al (2003) To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet 64(4):317–326
Godino L, Skirton H (2012) A systematic review of nurses’ knowledge of genetics. J Nurs Educ Pract 2(3):173–184
Green RC, Berg JS, Grody WW et al (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15(7):565–574
Grover S, Stoffel EM, Bussone L et al (2004) Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2(9):813–819
Hallowell N, Foster C, Eeles R et al (2004) Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer. Soc Sci Med 59(3):553–565
House of Lords Science and Technology Committee (2009) Genomic medicine, 7 July
Hughes C, Lerman C, Schwartz M et al (2002) All in the family: evaluation of the process and content of sisters’ communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 107(2):143–150
Hurvitz SA, Hu Y, O’Brien N, Finn RS (2013) Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39(3):219–229
Julian-Reynier C, Eisinger F, Chabal F et al (1998) Cancer genetic clinics: why do women who already have cancer attend? Eur J Cancer 34(10):1549–1553
Lanceley A, Eagle Z, Ogden G et al (2012) Family history and women with ovarian cancer: is it asked and does it matter?: an observational study. Int J Gynecol Cancer 22(2):254–259
Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 14(12):1060–1074
Metcalfe A, Pumphrey R, Clifford C (2010) Hospice nurses and genetics: implications for end-of-life care. J Clin Nurs 19(1–2):192–207
Meyer LA, Anderson ME, Lacour RA et al (2010) Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 115(5):945–952
Michie S, Smith JA, Senior V, Marteau TM et al (2003) Understanding why negative genetic test results sometimes fail to reassure. Am J Med Genet A 119A(3):340–347
National Institute for Health and Care Excellence (2013) Familial Breast Cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer CG164, London
Rahman N (2014a) Realizing the promise of cancer predisposition genes. Nature 505:302–308
Rahman N (2014b) Mainstreaming genetic testing of cancer predisposition genes. Clin Med 14(4):436–439
Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (Aug 31)
Roskoski RJR (2015) A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 100:1–23
Royal College of Physicians Royal College of Pathologists and British Society for Human Genetics (2011) Consent and confidentiality in clinical genetic practice: guidance on genetic testing and sharing genetic information, 2nd edn. Report of the Joint Committee on Medical Genetics, London
Scheuner M, Sieverding P, Shekelle P (2008) Delivery of genomic medicine for common chronic adult diseases: a systematic review. J Am Med Assoc 299:1320–1334
Scott CL, Swisher EM, Kaufmann SH (2015) Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 33(12):1397–1406
Shked-Rafid S, Dheensa S, Crawford G et al (2014) Defining and managing incidental findings in genetic and genomic practice. J Med Genet 51(715):723 (Published online 16.09.14)
Thomas F, Hennebelle I, Delmas C et al (2015) Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther. doi:10.1002/cpt.210 [Epub ahead of print]
Vansenne F, Bossuyt PM, de Borgie CA (2009) Evaluating the psychological effects of genetic testing in symptomatic patients: a systematic review. Genet Test Mol Biomarkers 13:555–563
Wright CF, Middleton A, Burton H (2013) Policy challenges of clinical genome sequencing. BMJ 2013:347–353
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jacobs, C., Pichert, G. (2016). Genetic Testing for Rare Cancer: The Wider Issues. In: Pichert, G., Jacobs, C. (eds) Rare Hereditary Cancers. Recent Results in Cancer Research, vol 205. Springer, Cham. https://doi.org/10.1007/978-3-319-29998-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-29998-3_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29996-9
Online ISBN: 978-3-319-29998-3
eBook Packages: MedicineMedicine (R0)